171 related articles for article (PubMed ID: 36044040)
1. In vivo functional characterization of EGFR variants identifies novel drivers of glioblastoma.
Yu K; Kong K; Lozzi B; Luna-Figueroa E; Cervantes A; Curry R; Mohila CA; Rao G; Jalali A; Mills GB; Scott KL; Deneen B
Neuro Oncol; 2023 Mar; 25(3):471-481. PubMed ID: 36044040
[TBL] [Abstract][Full Text] [Related]
2. PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas.
Noorani I; de la Rosa J; Choi YH; Strong A; Ponstingl H; Vijayabaskar MS; Lee J; Lee E; Richard-Londt A; Friedrich M; Furlanetto F; Fuente R; Banerjee R; Yang F; Law F; Watts C; Rad R; Vassiliou G; Kim JK; Santarius T; Brandner S; Bradley A
Genome Biol; 2020 Jul; 21(1):181. PubMed ID: 32727536
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
4. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
5. The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.
Johansson M; Oudin A; Tiemann K; Bernard A; Golebiewska A; Keunen O; Fack F; Stieber D; Wang B; Hedman H; Niclou SP
Neuro Oncol; 2013 Sep; 15(9):1200-11. PubMed ID: 23723255
[TBL] [Abstract][Full Text] [Related]
6. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling.
Oh H; Hwang I; Jang JY; Wu L; Cao D; Yao J; Ying H; Li JY; Yao Y; Hu B; Wang Q; Zheng H; Paik J
Cancer Res; 2021 Mar; 81(6):1528-1539. PubMed ID: 33509942
[TBL] [Abstract][Full Text] [Related]
7. A case of glioblastoma harboring non-amplified epidermal growth factor receptor variant III: Critical molecular detection using RNA-based panel analysis.
Kirishima M; Akahane T; Takajo T; Higa N; Yonezawa H; Uchida H; Kamimura K; Hanaya R; Yoshimoto K; Higashi M; Yoshiura T; Tanimoto A
Pathol Res Pract; 2023 Aug; 248():154712. PubMed ID: 37499520
[TBL] [Abstract][Full Text] [Related]
8. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor.
Klingler-Hoffmann M; Fodero-Tavoletti MT; Mishima K; Narita Y; Cavenee WK; Furnari FB; Huang HJ; Tiganis T
J Biol Chem; 2001 Dec; 276(49):46313-8. PubMed ID: 11514572
[TBL] [Abstract][Full Text] [Related]
9. FHL2 interacts with EGFR to promote glioblastoma growth.
Sun L; Yu S; Xu H; Zheng Y; Lin J; Wu M; Wang J; Wang A; Lan Q; Furnari F; Cavenee W; Purow B; Li M
Oncogene; 2018 Mar; 37(10):1386-1398. PubMed ID: 29321665
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
11. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop.
Zhang X; Niu W; Mu M; Hu S; Niu C
J Exp Clin Cancer Res; 2020 Sep; 39(1):196. PubMed ID: 32962742
[TBL] [Abstract][Full Text] [Related]
13. Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation.
Furgason JM; Li W; Milholland B; Cross E; Li Y; McPherson CM; Warnick RE; Rixe O; Stambrook PJ; Vijg J; Bahassi el M
Mutagenesis; 2014 Sep; 29(5):341-50. PubMed ID: 25103728
[TBL] [Abstract][Full Text] [Related]
14. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
[TBL] [Abstract][Full Text] [Related]
15. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk.
Andersson U; Schwartzbaum J; Wiklund F; Sjöström S; Liu Y; Tsavachidis S; Ahlbom A; Auvinen A; Collatz-Laier H; Feychting M; Johansen C; Kiuru A; Lönn S; Schoemaker MJ; Swerdlow AJ; Henriksson R; Bondy M; Melin B
Acta Oncol; 2010 Aug; 49(6):767-75. PubMed ID: 20446891
[TBL] [Abstract][Full Text] [Related]
17. A non-hierarchical organization of tumorigenic NG2 cells in glioblastoma promoted by EGFR.
Al-Mayhani TF; Heywood RM; Vemireddy V; Lathia JD; Piccirillo SGM; Watts C
Neuro Oncol; 2019 Jun; 21(6):719-729. PubMed ID: 30590711
[TBL] [Abstract][Full Text] [Related]
18. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma.
Rodriguez SMB; Kamel A; Ciubotaru GV; Onose G; Sevastre AS; Sfredel V; Danoiu S; Dricu A; Tataranu LG
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446288
[TBL] [Abstract][Full Text] [Related]
19. EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.
Francis JM; Zhang CZ; Maire CL; Jung J; Manzo VE; Adalsteinsson VA; Homer H; Haidar S; Blumenstiel B; Pedamallu CS; Ligon AH; Love JC; Meyerson M; Ligon KL
Cancer Discov; 2014 Aug; 4(8):956-71. PubMed ID: 24893890
[TBL] [Abstract][Full Text] [Related]
20. HBEGF promotes gliomagenesis in the context of Ink4a/Arf and Pten loss.
Shin CH; Robinson JP; Sonnen JA; Welker AE; Yu DX; VanBrocklin MW; Holmen SL
Oncogene; 2017 Aug; 36(32):4610-4618. PubMed ID: 28368403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
